Carl Zeiss Meditec AG (LTS:0DHC) Change In Working Capital

: €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Carl Zeiss Meditec AG's change in working capital for the quarter that ended in Dec. 2023 was €0 Mil.

Carl Zeiss Meditec AG's change in working capital for the fiscal year that ended in Sep. 2023 was €-126 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Carl Zeiss Meditec AG Change In Working Capital Historical Data

The historical data trend for Carl Zeiss Meditec AG's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Working Capital

-0.52

-5.11

51.65

-109.51

-125.88

Carl Zeiss Meditec AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital																-	-	-	-	-

Carl Zeiss Meditec AG Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Carl Zeiss Meditec AG Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (LTS:0DHC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (LTS:0DHC) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

CZMWY:USA CZMWF:USA 1AFX:Italy AFXd:UK AFX:Germany AFX:Austria

Address

Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745

Website

https://www.zeiss.com

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Carl Zeiss Meditec AG (LTS:0DHC) Headlines

No Headlines